Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib

BACKGROUND. Ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL) that inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. METHODS. We used stable isotopic labeling with deuterated water ((2)H(2)O) to measure directly the...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JCI Insight
Päätekijät: Burger, Jan A., Li, Kelvin W., Keating, Michael J., Sivina, Mariela, Amer, Ahmed M., Garg, Naveen, Ferrajoli, Alessandra, Huang, Xuelin, Kantarjian, Hagop, Wierda, William G., O’Brien, Susan, Hellerstein, Marc K., Turner, Scott M., Emson, Claire L., Chen, Shih-Shih, Yan, Xiao-Jie, Wodarz, Dominik, Chiorazzi, Nicholas
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2017
Aiheet:
Clinical Medicine
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5256142/
https://ncbi.nlm.nih.gov/pubmed/28138560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.89904
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia